Open Now: The Global ETF Survey Take the Survey →

Advertisement
Advertisement
Segment| Data as of 07/27/2026
trending up

Tomorrow's Treatments ETFs

1D perf
0.45%
1D flows
-
Total AuM
$685M
Total ETFs
9

Aggregate data of 9 funds

Performance

-2.0-1.00.01.02.03.04.05.0%Jun 29Jul 6Jul 13Jul 20Jul 27

Flows

-10 M0 M10 M20 M30 M40 M
1M3MYTD1Y3Y5Y
Perf.+1.38%+11.51%+17.41%+60.58%+72.54%
Flows+$34M+$67M+$159M+$205M+$312M-

Top ETFs in this segment

1D-0.04%1W flows-View
1D+1.07%1W flows-View
1D+0.52%1W flows-View
Advertisement

Just published in Tomorrow's Treatments

View all articles

Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities

Small-cap biotech ETFs focus on early-stage companies, offering explosive upside potential but higher risks compared to market-cap weighted competitors.

Biotech etfs

Movers in Tomorrow's Treatments

Top
Bottom
Top performers, 1 week1W perf.YTD perf.
MEDX
Horizon Kinetics Medical ETF+2.35%+6.90%
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF+2.24%+4.07%
CANC
Tema Oncology ETF+1.71%+18.41%
SBIO
ALPS Medical Breakthroughs ETF+1.42%+25.91%
THNR
Amplify Weight Loss Drug & Treatment ETF+0.90%+1.97%
Top inflows, 1 week1W flowYTD flows
OZEM
Roundhill GLP-1 & Weight Loss ETF-+$22M
ASD
Defiance Autism Impact ETF--
SBIO
ALPS Medical Breakthroughs ETF-+$41M
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF--$2M
MEDX
Horizon Kinetics Medical ETF--$3M

Data period: July 20 - 27, 2026

Performance lists exclude leveraged and inverse ETFs

Recently launched ETFs

Inception

Related indexes by ICE

NYFSGIB
NYSE FactSet Global Genomics and Immuno Biopharma IndexView on ICE
NYFSNBM
NYSE FactSet Global Neuro Biopharma and MedTech IndexView on ICE

Latest news about Thematic Investing: Tomorrow's Treatments

Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities

Small-cap biotech ETFs focus on early-stage companies, offering explosive upside potential but higher risks compared to market-cap weighted competitors.

Biotech etfs

Obesity and Weight-Loss Drugs: A New Thematic ETF Segment?

The ongoing Ozempic and weight-loss drug obsession has investors and ETF issuers turning to new ways of gaining healthcare sector exposure.

Weight-loss-drugs

Two biotech ETFs to watch for the rest of 2022 and beyond

Investors with a high tolerance for risk may seek to gain exposure to the growth potential of the biotech industry. We take a look at two ETFs that have rallied over the last month.

Two biotech ETFs to watch for the rest of 2022 and beyond
Advertisement
Advertisement
Advertisement
ETF U
Become a better investor with NYSE: The Home of ETFs
Visit the ETF U homepage
ETF Guides

Recent educational content

Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs July 20, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · July 20, 2026
Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs July 13, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · July 14, 2026
First Look ETF: Cash Deployment, Bond, and Hedged ETFs

First Look ETF

First Look ETF: Cash Deployment, Bond, and Hedged ETFs

In this season 6 episode of First Look ETF, Stephanie Stanton ‪examines the latest ETF marketplace trends with NYSE and guests.

ETF Guide
By ETF Guide · July 10, 2026
Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs July 6, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · July 7, 2026

Browse all educational columns

Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey and get exclusive early access to the final report.

Global ETF Survey 2026